

## **I. AMENDMENTS**

### **Claims**

Upon entry of the present amendment, the status of the claims will be as follows:

1 to 30. (Cancelled)

31. (Currently amended) A kit comprising:

(a) a microarray comprising a plurality of antibodies located at discrete locations on a solid surface wherein the antibodies are arranged in a spatially addressable ordered matrix; and

(b) a first reagent, for labeling a cell lysate with a first fluorescent dye, and a second reagent for labeling a cell lysate with a second fluorescent dye.

32. (Previously presented) A kit according to claim 31 further comprising instructions for comparing protein expression in two or more populations of cells or characterizing a cell based on the pattern of protein expression produced thereby.

33. (Original) A kit according to claim 31 wherein the antibodies are monoclonal antibodies, polyclonal antibodies or antibody fragments.

34. (Original) A kit according to claim 33 wherein the antibody fragments are single chain antibodies.

35. (Original) A kit according to claim 31 wherein the antibodies are recombinant antibodies.

36. (Original) A kit according to claim 31 further comprising reagents for detecting an antigen and instructions for use thereof.

37 to 50. (Cancelled)

51. (Previously Presented) The kit according to claim 31 wherein the source of the antibodies at each discrete location is known.

52 to 53. (Cancelled)

54. (Previously presented) The kit according to claim 31 wherein the space between the discrete locations is treated to minimize non-specific binding to the solid surface.

55 to 59. (Canceled)

60. (Previously presented) The kit according to claim 31, wherein between 0.01 nanoliters and 100 nanoliters of the antibodies are spotted at each discrete location on the solid surface.

61. (Previously presented) The kit according to claim 31, wherein the microarray comprises 600 discrete locations per square centimeter.

62. (Previously presented) The kit according to claim 51, wherein the source of the antibodies is a known hybridoma cell line.

63 to 65. (Canceled)

66. (Previously presented) The kit according to claim 31, wherein the plurality of antibodies recognize mammalian proteins.

67-68. (Canceled)

69. (Previously presented) The kit according to claim 31, further comprising a second microarray comprising a plurality of antibodies located at discrete locations on a second solid surface.

70. (Currently amended) A microarray comprising a plurality of antibodies located at discrete locations on a solid surface, wherein the antibodies are a collection of 1000 different antibodies and recognize proteins of a first species.

71. (Previously presented) The microarray according to claim 70, wherein the plurality of antibodies recognize mammalian proteins.

72. (Previously presented) The microarray according to claim 70, wherein between 0.01 nanoliters and 100 nanoliters of the antibodies are spotted at each discrete location on the solid surface.

73. (Previously presented) The microarray according to claim 70, wherein the microarray comprises 600 discrete locations per square centimeter.

74. (Previously presented) The kit according to claim 31, wherein the microarray comprises antibodies spotted at at least 48 discrete locations.

75. (Previously presented) The kit according to claim 74, wherein the microarray comprises antibodies spotted at at least 90 discrete locations .

76. (Previously presented) The kit according to claim 31, wherein the microarray comprises a collection of 1000 different antibodies.

77-79. (Cancelled)

80. (Previously presented) The microarray according to claim 70, wherein the microarray further comprises an antigen from a cell lysate, wherein the antigen is bound to a characterized antibody located on the solid surface.

81. (Previously presented) The kit according to claim 75, wherein the microarray comprises antibodies spotted at at least 384 discrete locations.

82. (Previously presented) The kit according to claim 31, wherein the microarray comprises antibodies spotted at at least 60 discrete locations, wherein the antibodies bind mammalian proteins.

83. (Previously presented) The kit according to claim 31, wherein the microarray comprises antibodies spotted at at least 192 discrete locations, wherein the antibodies bind mammalian proteins.